Foundation Year 2 for Peritoneal Malignancy

Hampshire Hospitals NHS Foundation Trust has a vacancy for a FY2 Trust doctor in Surgery at Basingstoke & North Hampshire Hospital.

This post is for 12 months (September 2026 to September 2027). The post holder will be working with the Peritoneal Malignancy surgery team and providing medical cover for the C2 ward.

The successful applicant will be part of a busy surgical unit which includes tertiary services for peritoneal malignancy. The post will suit SHO level doctors prior to a formal core training scheme, who wish to gain comprehensive exposure to acute and elective surgery. The operativeexposure is flexible and can be tailored to the experience and abilities of individual trainees. The post is designed to provide clinical and academic exposure to assist with application to training programs.

The post is based on the ward, but the successful candidate will have the opportunity to have a time to use to work in a clinical area to help them further advance their CV or clinical experience. This will be agreed prior to the successful candidate starting.

Although not recognised for training by the Royal College of Surgeons, the post offers an excellent opportunity for the successful candidate to build on existing knowledge and skills to strengthen and enhance their portfolio. Many of the previous
incumbents have been successful in gaining recognised training placements in their chosen schemes.

Our vision is to provide outstanding care for every patient. Patient care is at the heart of what we do at our three sites Basingstoke and North Hampshire Hospital, Royal Hampshire County Hospital in Winchester and Andover War Memorial Hospital. Hampshire Hospitals NHS Foundation Trust provides medical and surgical services to a population of approximately 600,000 across Hampshire and parts of West Berkshire

We provide specialist services to people across the UK and internationally. We are one of only two centres in the UK treating pseudomyxoma peritonei (a rare form of abdominal cancer) and we are leaders in the field of tertiary liver cancer and colorectal cancer.